Long-term efficacy of baricitinib in patients with rheumatoid arthritis who have had inadequate response to csDMARDs: results from ra-beyond up to 7 years of treatment

समान संसाधन

• Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study
  द्वारा: Caporali, R, और अन्य
  प्रकाशित: (2024)
• Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients
  द्वारा: Humby, F, और अन्य
  प्रकाशित: (2019)
• Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
  द्वारा: Keystone, E, और अन्य
  प्रकाशित: (2015)
• Rapid and concurrent improvements in patient-reported outcomes of rheumatoid arthritis with baricitinib in RA-BEAM
  द्वारा: Strand, V, और अन्य
  प्रकाशित: (2021)
• Patient disease trajectories in baricitinib-treated patients with rheumatoid arthritis and inadequate response to methotrexate
  द्वारा: Taylor, P, और अन्य
  प्रकाशित: (2019)